Company pipeline/regulatory timing: Xenon NDA for focal onset seizures under FDA review

Alongside the depression trial pause, Xenon disclosed that it has submitted an NDA to the FDA for azetukalner in focal epileptic seizures. The filing positions the same KV7 potassium channel opener for a new regulatory path, while investors track whether the epilepsy program’s existing efficacy and safety profile can offset the depression setbacks.